INSERM U1035, Bordeaux, France.
Mol Cancer. 2012 Oct 22;11:81. doi: 10.1186/1476-4598-11-81.
Pancreatic ductal adenocarcinoma is a deadly malignancy resistant to current therapies. It is critical to test new strategies, including tumor-targeted delivery of therapeutic agents. This study tested the possibility to target the transfer of a suicide gene in tumor cells using an oncotropic lentiviral vector.
Three cell surface markers were evaluated to target the transduction of cells by lentiviruses pseudotyped with a modified glycoprotein from Sindbis virus. Only Mucin-4 and the Claudin-18 proteins were found efficient for targeted lentivirus transductions in vitro. In subcutaneous xenografts of human pancreatic cancer cells models, Claudin-18 failed to achieve efficient gene transfer but Mucin-4 was found very potent. Human pancreatic tumor cells were modified to express a fluorescent protein detectable in live animals by bioimaging, to perform a direct non invasive and costless follow up of the tumor growth. Targeted gene transfer of a bicistronic transgene bearing a luciferase gene and the herpes simplex virus thymidine kinase gene into orthotopic grafts was carried out with Mucin-4 oncotropic lentiviruses. By contrast to the broad tropism VSV-G carrying lentivirus, this oncotropic lentivirus was found to transduce specifically tumor cells, sparing normal pancreatic cells in vivo. Transduced cells disappeared after ganciclovir treatment while the orthotopic tumor growth was slowed down.
This work considered for the first time three aspect of pancreatic adenocarcinoma targeted therapy. First, lentiviral transduction of human pancreatic tumor cells was possible when cells were grafted orthotopically. Second, we used a system targeting the tumor cells with cell surface antigens and sparing the normal cells. Finally, the TK/GCV anticancer system showed promising results in vivo. Importantly, the approach presented here appeared to be a safer, much more specific and an as efficient way to perform gene delivery in pancreatic tumors, in comparison with a broad tropism lentivirus. This study will be useful in future designing of targeted therapies for pancreatic cancer.
胰腺导管腺癌是一种对当前疗法具有耐药性的致命恶性肿瘤。测试新策略至关重要,包括将治疗剂靶向递送至肿瘤。本研究测试了使用修饰的辛德毕斯病毒糖蛋白对肿瘤细胞进行自杀基因转移的可能性。
评估了三种细胞表面标志物,以使用具有修饰的辛德毕斯病毒糖蛋白的嵌合慢病毒载体靶向转导细胞。只有黏蛋白-4 和 Claudin-18 蛋白被发现可有效地在体外进行靶向慢病毒转导。在人类胰腺癌细胞模型的皮下异种移植物中,Claudin-18 未能实现有效的基因转移,但发现 Mucin-4 非常有效。通过生物成像,将人胰腺肿瘤细胞修饰为可在活体动物中检测到的荧光蛋白,以直接进行非侵入性且无成本的肿瘤生长随访。使用 Mucin-4 癌靶向慢病毒进行了带有荧光素酶基因和单纯疱疹病毒胸苷激酶基因的双顺反子转基因的靶向基因转移,进入原位移植物。与广泛亲嗜性的 VSV-G 携带的慢病毒相比,这种癌靶向慢病毒被发现可特异性地转导肿瘤细胞,在体内保留正常的胰腺细胞。在用更昔洛韦处理后,转导的细胞消失,而原位肿瘤生长减慢。
这项工作首次考虑了胰腺腺癌靶向治疗的三个方面。首先,当细胞被原位移植时,人胰腺肿瘤细胞的慢病毒转导是可能的。其次,我们使用了一种靶向肿瘤细胞的系统,同时保留了正常细胞。最后,TK/GCV 抗癌系统在体内显示出有希望的结果。重要的是,与广泛亲嗜性的慢病毒相比,这里提出的方法似乎是一种更安全、更特异和同样有效的在胰腺肿瘤中进行基因传递的方法。这项研究将有助于未来设计针对胰腺肿瘤的靶向治疗。